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ABSTRACT
The teleost ®sh are widely used as model organisms
in vertebrate biology. The compact genome of the
puffer®sh, Fugu rubripes, has proven a valuable
tool in comparative genome analyses, aiding the
annotation of mammalian genomes and the identi®-
cation of conserved regulatory elements, whilst the
zebra®sh is particularly suited to genetic and devel-
opmental studies. We demonstrate that a puffer®sh
WT1 transgene can be expressed and spliced appro-
priately in transgenic zebra®sh, contrasting with the
situation in transgenic mice. By creating both trans-
genic mice and transgenic zebra®sh with the same
construct, we show that Fugu RNA is processed
correctly in zebra®sh but not in mice. Furthermore,
we show for the ®rst time that a Fugu genomic con-
struct can produce protein in transgenic zebra®sh:
a full-length Fugu WT1 transgene with a C-terminal
b-galactosidase fusion is spliced and translated cor-
rectly in zebra®sh, mimicking the expression of the
endogenous WT1 gene. These data demonstrate
that the zebra®sh:Fugu system is a powerful and
convenient tool for dissecting both vertebrate gene
regulation and gene function in vivo.
INTRODUCTION
The Wilms' tumour suppressor gene, WT1, was originally
identi®ed as a gene deleted or rearranged in Wilms' tumour
(1,2), and WT1 mutations have been shown to cause both
Frasier (3) and Denys±Drash (4) syndromes. The gene
encodes a four zinc ®nger-containing nuclear protein with
roles both as a transcription factor and in RNA processing
[reviewed in Englert (5)]. In addition to human genitourinary
disorders, further evidence of the fundamental role of WT1 in
genitourinary development is provided by WT1-null mice,
which display a complete absence of kidney and gonad
structures and die in mid-gestation (6). A combination of
alternative splicing, alternative translation initiation and RNA
editing gives rise to at least 16 distinct protein isoforms
(5,7,8).
WT1 has been conserved throughout vertebrate evolution,
although only mammals possess numerous protein isoforms
(9,10). Non-mammalian vertebrates possess just two different
protein isoforms resulting from an alternative splicing event
which can insert three amino acids between the third and
fourth zinc ®ngers. Given that the genitourinary system has
evolved dramatically throughout vertebrate radiation, it is
tempting to speculate that the complexity of mammalian WT1
isoforms may be associated with changes to the genitourinary
system, whilst the three amino acid alternative splice is
involved in a basic function conserved through vertebrate
evolution (11). The expression pattern of WT1 has been
conserved throughout vertebrates, with WT1 expression being
demonstrated in the developing genitourinary system of chick,
alligator, Xenopus and zebra®sh, as well as mammals
(9,12±15). However, it should be noted that WT1 is also
expressed in genitourinary structures that are speci®c to
mammals, such as the endometrium (16). Consequently,
whilst evolutionary conservation may point to the basic
function(s) of WT1, evolutionary differences could shed light
on the acquisition of novel regulatory and functional proper-
ties during the evolution of an organ system.
The puffer®sh, Fugu rubripes, has a genome that is
approximately 7.5 times smaller than that of human, with
compaction occurring within both introns and intergenic
regions (17). The relatively small size of the Fugu genome has
enabled a large amount of sequence data to be generated (18)
(http://fugu.hgmp.mrc.ac.uk), thereby facilitating base-by-
base comparison of ®sh and mammalian genomes (e.g.
Fugu:human) and providing a framework onto which other
genomes such as zebra®sh and mouse may be superimposed.
Typically, coding sequences are highly conserved between
Fugu and mammals, and the randomisation of non-coding
DNA sequences has led to the identi®cation of regulatory
elements associated with genes based upon non-coding DNA
sequence conservation (19). Recent studies have demonstrated
the usefulness of zebra®sh transgenesis as a means of
dissecting complex regulatory elements of Fugu genes (20).
The strategy of using Fugu transgenes in zebra®sh bene®ts
from being a heterologous system, with the transgene readily
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distinguishable from the endogenous gene, without the
drawbacks of using evolutionarily distant species such as
mouse in which high level tissue-speci®c expression of
transgenes is not guaranteed (21).
Despite the widespread use of Fugu as a model organism for
genome comparisons and the proven worth of utilising its
compact genome to identify and characterise regulatory
elements, entire Fugu genes have not been exploited for
functional studies. The compact nature of Fugu genes suggests
they would be a very useful source of genomic DNA
constructs for transgenesis, with the advantage over cDNA
constructs of being able to generate all isoforms of a particular
gene, expressed from their own regulatory elements. The
recently sequenced human genome (22,23) possesses fewer
genes than predicted, and it has been suggested that alternative
splicing may account for this discrepancy, resulting in a
proteome of far greater complexity than the genome (24).
Consequently, the ability to express all isoforms of a particular
gene for functional studies is an important consideration.
To evaluate the potential of Fugu transgenes, Sathasivam
et al. introduced the Fugu homologue of the Huntingdon's
disease gene into a mouse cell line and created a line of
transgenic mice harbouring a genomic Fugu HD construct
(25). Despite detecting transgene expression, the Fugu HD
transcript was aberrantly processed, with the inclusion of
introns often giving rise to in-frame stop codons incompatible
with production of full-length protein.
In this study, we have con®rmed that Fugu RNAs are
spliced incorrectly in transgenic mice, consistent with the
aberrant splicing of Fugu HD observed by Sathasivam et al.
Our data suggest there may be a general inability of Fugu
RNAs to be processed correctly in mammalian cells due to
inherent differences in splicing between ®sh and mammals.
Consistent with this, we show that Fugu introns are spliced
correctly in transgenic zebra®sh and that the complete Fugu
WT1 gene is expressed in the correct tissue-speci®c manner
under its own regulatory elements. Furthermore, this expres-
sion results in correct mRNA processing and translation
leading to faithful expression of the heterologous protein in
transgenic zebra®sh, demonstrating for the ®rst time that Fugu
genomic transgenes can be used to express Fugu proteins in
transgenic zebra®sh.
MATERIALS AND METHODS
DNA constructs
WT1-containing cosmids were isolated from a gridded cosmid
library of F.rubripes genomic DNA [Greg Elgar, Human
Genome Mapping Project Resource Centre (HGMP-RC)], as
described (10). Unmodi®ed constructs for mouse transgenesis
were isolated directly from Fugu cosmids by restriction
digestion. Fugu RCN1 (Fig. 1A) was isolated as an 18 kb
HindIII fragment from cosmid 151J19, and Fugu WT1
(Fig. 1C) as a 12 kb BamHI±XbaI fragment from cosmid
104M11.
The splicing construct HAFrWT1MYC was created by
cloning exons 5±9 of Fugu WT1 from 151J19 (Fig. 1B) into a
modi®ed pCI-neo (Promega) carrying three N-terminal
haemagglutinin (HA) tags and a C-terminal myc tag (26).
For microinjection into mouse oocytes, the transgene was
liberated from vector sequences by BglII±NaeI digestion.
pXIG (a kind gift from Adam Amsterdam) consists of the
green ¯uorescent protein (GFP)-coding sequence under con-
trol of the Xenopus elongation factor 1a promoter. This
construct directs ubiquitous GFP expression in transgenic
zebra®sh (27) and was injected in its supercoiled form to
obtain transient expression in zebra®sh embryos.
To create pFrWTlac for ®sh transgenesis, Fugu WT1 was
®rst cloned into pPolyIII as a 12 kb BamHI±XbaI fragment
(Fig. 1C). A b-galactosidase gene, stop and polyadenylation
sequences were cloned into the SphI site in exon 9, using
oligonucleotide linkers to create a fusion construct, retaining
the open reading frame and allowing release of the construct
by NotI digestion.
Production of transgenic animals
Constructs for transgenic mice were digested using the
restriction enzymes described above, gel puri®ed to remove
all vector sequences and injected into fertilised (CBA 3
C57Bl/6)F2 oocytes at ~5 ng/ml. Positive founder mice were
identi®ed by Southern blot, bred with (CBA 3 C57Bl/6)F1
mice and lines were maintained as heterozygotes. Transient
transgenic embryos were harvested 10 days after oviduct
transfer of microinjected oocytes into pseudopregnant recipi-
ents and genotyped by PCR of embryonic tail DNA with
transgene-speci®c primers.
Transgenic zebra®sh were obtained by injecting single
blastomeres of one- and two-cell stage zebra®sh embryos
(Gol±/±) with pHAFrWT1MYC at ~15 ng/ml. Co-injection with
the ubiquitously expressing GFP vector, pXIG (27), enabled
selection of transgenic (expressing) embryos.
Analysis of transgenic animals
Total RNA was isolated from mouse tissues, whole mouse
embryos and zebra®sh embryos using the RNAgents isolation
system (Promega), then subjected to DNase I treatment
(Roche Diagnostics) and a second phenol/choloroform extrac-
tion and precipitation. Fugu RNA was obtained from the MRC
HGMP-RC and subjected to DNase I treatment (Roche
Diagnostics) prior to reverse transcription. For DNA ampli-
®cation, Fugu RNA was subjected to PCR without reverse
transcription and prior to DNase I treatment. RT±PCR was
performed either by using the Access RT±PCR kit (Promega)
or by reverse transcribing total RNA using an oligo(dT) primer
followed by 30 cycles of intron-speci®c PCR. To control for
differences in ampli®cation of particular PCR products during
thermal cycling and preferential ampli®cation due to vari-
ations in template concentration, PCRs were also carried out
over a range of cycle numbers (24, 26, 28 and 30 cycles) or
with varying amounts of starting template. Control RT±PCRs
were performed to normalise loading and verify DNase I
treatment using primers for HPRT or RCN1 (mouse) and
cyclin D (zebra®sh). The identity of correctly sized RT±PCR
products was con®rmed by Southern blot and hybridisation
with [g-32P]ATP-labelled internal oligonucleotides (oligo-
nucleotide sequences available on request).
For X-gal staining, zebra®sh embryos were ®xed for 45 min
in 4% paraformaldehyde (PFA) at room temperature,
dechorionated in phosphate-buffered saline (PBS), washed
in PBS containing 0.1% Tween 20 (PBT) and stained in X-gal
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stain solution [Na2HPO4/NaH2PO4, NaCl, K4Fe3(CN)6/
K3Fe(CN)6 plus 0.7 mg/ml X-gal] at 37°C for between 1
and 6 h.
Zebra®sh whole-mount in situ hybridisation was performed
essentially as described (28) using the full-length zebra®sh
WT1 cDNA (GenBank accession no. AF144550) as a probe.
Hybridisation of the digoxigenin-labelled riboprobe was
detected using anti-DIG Fab-AP (1:5000) in combination
with NBT/BCIP substrates (Roche). Embryos were equili-
brated to 80% glycerol for photography.
RESULTS
Aberrant splicing of Fugu genes in transgenic mice
The compact nature of the Fugu genome suggests that Fugu
transgenes may provide natural minigenes for transgenesis to
study both gene regulation and gene function. We have
previously cloned the Fugu equivalent of human chromosome
11p13, the WAGR region, and demonstrated that this locus is
highly conserved between ®sh and mammals; gene order and
orientation are conserved, as are numerous non-coding
regions, such as known Pax6 regulatory elements (10). This
conservation implies that the Fugu WAGR region is a good
model for its mammalian equivalent, and the existence of
mouse strains carrying a range of deletions across this region
(29,30) makes it an attractive locus at which to perform
transgenic rescue experiments in mice.
As a ®rst step towards this goal, we generated eight lines of
transgenic mice via pronuclear injection of either Fugu RCN1
or Fugu WT1 into fertilised, wild-type, F1 oocytes. Two out of
the ®ve lines of Fugu RCN1 transgenic mice displayed
widespread transgene expression, consistent with the expres-
sion pattern of endogenous RCN1. Transgene expression was
only detectable in one line of Fugu WT1 transgenic mice, with
expression restricted to the thymus (not shown). As endogen-
ous WT1 is not expressed in the thymus, this represents a site
of ectopic transgene expression, suggesting either that the
Fugu WT1 transgene lacks important regulatory elements or
that the species differences between puffer®sh and mammals
are too great for reliable Fugu WT1 expression in transgenic
mice.
We performed RT±PCR to determine whether the compact
Fugu transgenes were spliced correctly and thus were capable
of generating full-length protein. Consistent with previous
transgenic mice expressing Fugu HD (25), aberrant splicing
was observed in all three expressing lines of transgenic mice.
To investigate this aberrant splicing in detail, RT±PCR was
performed on a panel of tissues from the highest expressing
Fugu RCN1 line across speci®c intron±exon boundaries
(Fig. 2). Fugu RCN1 introns of <200 bp were not spliced in
transgenic mice (introns 2 and 5), whilst the 1.22 kb intron 1
was fully spliced. Introns 3 and 4 (1.23 kb and 250 bp,
respectively), however, were partly spliced. In contrast,
RT±PCR analysis of Fugu RNA showed that the endogenous
RCN1 RNA was fully spliced in vivo, with no evidence of
unspliced RNA even at limiting cycle number. The doublet
arising from ampli®cation of intron 4 is likely to be due to a
pseudogene which has been identi®ed elsewhere in the Fugu
genome. It has been suggested that Fugu introns are too small
to be spliced ef®ciently by the mammalian splicing machinery
(25). The observation that Fugu RCN1 intron 1 (1.22 kb) is
fully spliced whilst intron 3 (1.23 kb) is poorly spliced implies
that intron size alone is not suf®cient to account for this
phenomenon. Consistent with this, mammalian cells are
capable of ef®ciently splicing introns of <100 bp, e.g. intron
17 of human HD is 93 bp (31).
Ef®cient splicing of Fugu introns in transgenic zebra®sh
Given that species differences rather than intron size were the
likely cause of aberrant splicing in Fugu transgenic mice, we
tested whether Fugu introns could be processed correctly in a
transgenic ®sh system.
To facilitate direct comparison between transgenic mice
and transgenic zebra®sh, a cytomegalovirus (CMV)-driven
Fugu WT1 splicing construct was utilised. This construct,
pHAFrWT1MYC, consisted of a CMV promoter driving
expression of a genomic fragment encompassing Fugu WT1
exons 5±9 (Fig. 1B), with in-frame N- and C-terminal tags to
facilitate speci®c detection of transgenic transcripts by
RT±PCR. The Fugu WT1 introns within this construct range
in size from 80 to 500 bp (Fig. 3A).
We generated 15 transient transgenic mouse embryos with
pHAFrWT1MYC. Microinjected embryos were taken at
e10.5, genotyped by PCR of DNA extracted from the embryo
tail and total RNA was isolated from individual whole
embryos. In all transient transgenic mouse embryos, in-
ef®cient splicing was observed across individual introns and,
when splicing was analysed across two introns, almost no
correctly spliced transcripts were detectable. Figure 3B shows
RT±PCR analysis of splicing across exons 7±9 for two
transgenic mice, M10 and M14, representative of low and high
expressors, respectively. Given the inef®ciency of splicing
across two introns, it is unlikely that any correctly spliced
Figure 1. Scale drawing of the Fugu rubripes WAGR region encompassing WT1, RCN1 and PAX6 genes depicting the constructs used in this study. (A)
Fugu RCN1. (B) PHAFrWT1MYC. (C) Fugu WT1/pFrWTlac.
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full-length mRNA would be produced in transgenic mice
harbouring a complete Fugu WT1 gene. The splicing defects
observed in HAFrWT1MYC transgenic embryos were not
restricted to intron inclusion, with exon skipping being
observed in highly expressing individuals.
The skipping of exon 8 and the correct splicing of exons 7±9
of Fugu WT1 were only detectable by conventional RT±PCR
at low levels in highly expressing transgenic mice, suggesting
that these are rare events and that intron inclusion is the most
common splicing defect when Fugu genes are expressed in
mouse cells. The inclusion of either intron 7 or intron 8 would
result in four (intron 7) or three (intron 8) in-frame
translational stop codons within the aberrantly spliced mRNA.
To directly compare splicing ef®ciency of this transgene
between mice and ®sh, we generated transgenic zebra®sh via
co-injection of pHAFrWT1MYC and pXIG. Transgenic
embryos were selected for green ¯uorescence at 10±12
hours post-fertilisation (h.p.f.), pooled in groups of between
15 and 30, and total RNA was isolated from separate pools for
RT±PCR analysis. Two representative pools of transgenic
zebra®sh embryos are shown in Figure 3B. In contrast to
transgenic mouse embryos, splicing of the transgene in
zebra®sh embryos was far more ef®cient. To control for
saturation effects in the PCRs, ZF28 and M10 samples were
subject to PCR for between 24 and 30 cycles (Fig. 3C),
showing that the aberrantly spliced RNA can be detected in
transgenic mouse embryos at limiting cycle number and that
no unspliced RNA is detected in transgenic zebra®sh embryos.
Thus the same Fugu construct is spliced ef®ciently in
zebra®sh but not in mice, suggesting that the differences
affecting splicing are not speci®c to the puffer®sh but re¯ect
species differences between ®sh and mammals in general.
The alternative splicing of three amino acids between zinc
®ngers 3 and 4 of WT1 is crucial for WT1 function within the
genitourinary system and is conserved throughout all verte-
brates (9±11). This alternative splicing event is not regulated
by a tissue-speci®c factor and even occurs in transfected cells
not expressing endogenous WT1 (26). Given the ef®ciency
with which the Fugu WT1 construct was spliced in transgenic
zebra®sh, we used RT±PCR to determine whether the
transgene was also alternatively spliced. RT±PCR analyses
from exon 8 to exon 9 on pools of transgenic zebra®sh
demonstrate that the Fugu WT1 construct is alternatively
spliced (Fig. 3D) and that Fugu genomic transgenes have the
potential to give rise to the full range of alternatively spliced
WT1 transcripts in zebra®sh. We also analysed
pHAFrWT1MYC transgenic mouse embryos in which low
levels of correctly spliced product were observed using
RT±PCR from exon 8 to exon 9 but with the addition of
[32P]dCTP to the reaction. By increasing sensitivity in this
way, we found that the Fugu construct also exhibits alternative
splicing in transgenic mice (data not shown), consistent with
the ubiquitous nature of this alternative splicing event.
Protein expression from a full-length Fugu WT1
transgene in zebra®sh
The ef®ciency with which the Fugu genomic construct is
spliced in ®sh suggests that full-length Fugu mRNA can be
Figure 2. A Fugu RCN1 transgene is not spliced ef®ciently in transgenic mice. (A) Diagram of the Fugu RCN1 genomic transgene showing intron sizes. The
sizes of the corresponding mouse introns are shown in parentheses. (B±F) RT±PCR analysis of splicing for individual introns of Fugu RCN1 in transgenic
mice. (B) Intron 1, (C) intron 2, (D) intron 3, (E) intron 4, (F) intron 5. Total RNA prepared from kidney of transgenic Fugu RCN1 mice was subjected to
RT±PCR across individual intron±exon boundaries. Lane b, H2O blank. (G and H) RT±PCR analysis of the endogenous Fugu RCN1 RNA in puffer®sh
kidney. Lane d, DNA ampli®cation; negative control (±) consisting of an equivalent amount of the total RNA preparation subjected to PCR without reverse
transcription; PCR of reverse-transcribed RNA (+). RT±PCR products corresponding to spliced and unspliced introns are labelled s and u, respectively.
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produced in transgenic zebra®sh. To test this directly and to
determine whether Fugu mRNA can be translated in zebra®sh
to produce full-length protein, we modi®ed the complete Fugu
WT1 gene and ¯anking genomic regions to include a
histochemical marker (b-galactosidase) fused to the penulti-
mate codon of WT1, such that only faithful splicing and
translation of the resulting fusion mRNA would produce a
fusion protein detectable by X-gal staining (Fig. 4A).
We injected pFrWTlac into fertilised zebra®sh eggs.
Approximately 10% of injected embryos displayed X-gal
staining, demonstrating that the full-length genomic Fugu
WT1 transgene was indeed correctly spliced and translated to
produce full-length protein. Injected embryos were stained
between 10 and 72 h.p.f. At 24 h.p.f., the degree of mosaicism
associated with zebra®sh transgenesis resulted in expression
being restriced to small `clones' of cells (data not shown). At
12 h.p.f., it was possible to identify transgenic embryos with
more complete expression patternsÐtypically within the
developing pronephros (Fig. 4C)Ðalthough individual
embryos exhibited a great deal of mosaicism (compare
Fig. 4D and E). The expression pattern of the Fugu transgene
observed at 12 h.p.f. recapitulated that of endogenous
zebra®sh WT1 (Fig. 4B). X-gal staining of zebra®sh embryos
injected with pFrWTlac at later time points (48 and 72 h.p.f.)
revealed no transgenic ®sh, with numerous embryos dying or
developing abnormally. By performing zebra®sh injections
with a modi®ed pFrWTlac (pFrWTGFP) containing GFP in
place of lacZ, we con®rmed that expression of the transgene,
as determined by GFP expression in un®xed zebra®sh
embryos, was associated with abnormal development and
lethality (not shown). This ®nding is consistent with the
suggestion that overexpression of WT1 in transgenic mice
causes embryonic lethality in vivo (32).
DISCUSSION
In this study, we demonstrate that Fugu transgenes are
aberrantly spliced in transgenic mice and yet are correctly
spliced in transgenic zebra®sh. Furthermore, we show that
Fugu WT1 is expressed faithfully in the developing kidney of
transgenic zebra®sh, resulting in the production of a marked
Fugu WT1 protein from the transgene. These observations
broaden the utility of Fugu as a model system to include
Figure 3. Ef®cient splicing of a Fugu rubripes transgene in zebra®sh but not in mice. (A) Diagram of pHAFrWT1MYC showing intron sizes, with the sizes
of the corresponding mouse introns in parentheses. The asterisk refers to the location of the three amino acid alternative splicing event. Note that ®sh do not
possess an equivalent to mammalian WT1 exon 5. Consequently, Fugu WT1 exon 6 corresponds to mammalian exon 7 and so on. (B) RT±PCR analysis of
transgenic zebra®sh pools, ZF14 and ZF28, and individual transgenic mouse embryos, M10 and M14, selected to represent low and high expressors
respectively. RT±PCR was performed on total RNA isolated from whole embryos using oligonucleotides situated in exon 7 and the myc tag. The negative
control consists of an equivalent amount of the total RNA preparation subjected to PCR without reverse transcription, b = H2O blank. RT±PCR products
corresponding to each partly spliced transcript are labelled. (C) RT±PCR analysis of ZF28 and M10 RNA from exon 7 to MYC showing the emergence of
each class of PCR product from 24 to 30 cycles. An equivalent amount of RNA was ampli®ed for 30 cycles without reverse transcription as a control (±RT),
b = H2O blank. (D) Analysis of alternative splicing of the transgene in pools of transgenic zebra®sh (ZF14 and ZF28) harbouring pHAFrWT1MYC. RT±PCR
was performed with oligonucleotides situated in exon 8 and the myc tag. The negative control (±) consists of an equivalent amount of the total RNA
preparation subjected to PCR without reverse transcription.
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functional experiments in vivo using Fugu genes in transgenic
zebra®sh.
Fugu introns are spliced ef®ciently in transgenic
zebra®sh but not transgenic mice
The failure of Fugu transgenes to be spliced accurately in
mammalian cells is consistent with a previous study of Fugu
HD in which Sathasivam et al. speculate that the small size of
Fugu introns stresses the ®delity of the mammalian splicing
apparatus (25). Whilst our data support this, they also suggest
that the size of a particular intron is not the only factor
determining whether that intron is spliced ef®ciently.
Consistent with this, many mammalian introns are <250 bp
(33).
A survey of more than 100 splice site mutations found that
the most common consequence of splice site mutation was
exon skipping, with intron inclusion only observed in 6% of
cases (34). In contrast, intron inclusion is the most common
splicing defect observed when Fugu genes are expressed in
mouse cells. Therefore, it seems unlikely that speci®c
sequence differences can fully explain the aberrant splicing
of Fugu constructs in mouse cells, as such differences might
be expected to result in exon skipping. In addition, the fact that
individual Fugu introns can be partially spliced suggests that
this phenomenon is related to evolutionary differences at the
level of splicing ef®ciency between ®sh and mammals, in
general. This implies that Fugu resembles other teleosts at the
level of splicing despite its compact genome. It may be that
these evolutionary differences between splicing in ®sh and
mammals could be exploited to further understand the
fundamental mechanisms underlying splicing in vertebrates.
Typically, vertebrate genes possess large introns and small
exons, whilst the genes of lower eukaryotes possess small
introns and relatively large exons (35). These differences form
the basis of the intron versus exon de®nition models of
splicing (36). Fugu, however, is an exception in that its genes
display vertebrate exon organisation with generally small
introns (17). This reduction in intron size whilst retaining exon
size compared with other vertebrates may, as these models
predict, stress the ®delity of the splicing machinery of mouse
cells. Intriguingly, the observation that Fugu introns are
spliced ef®ciently in zebra®sh would suggest general species
differences in intron versus exon de®nition between ®sh and
mammals, rather than a phenomenon unique to Fugu. Cross-
species transgenesis may provide an interesting way in which
to study these fundamental splicing decisions which, to date,
have been addressed by making changes to a splicing
construct within a constant cell system. By keeping the
splicing construct constant and changing the cell (species)
type, parameters such as ionic strength, factor concentration
and temperature may be affecting the activity of splicing
factors or the con®guration of pre-mRNA (37±39). In light of
this, it is interesting to note the recent characterisation of an
alternative splicing event within the human neuro®bromatosis
type 1 mRNA which is induced by cold stress of 25°C (40).
The genomes of both the puffer®sh (http://fugu.
hgmp.mrc.ac.uk) and the zebra®sh (http://www.sanger.ac.uk/
Projects/D_rerio) are in the process of being fully sequenced.
The complete genome sequence of these two teleost ®sh will
enable detailed genomic comparisons to be made between ®sh
and mammals, and will complement cross-species transgenic
experiments of the kind described herein. In particular, the
comparison of transgenic mice harbouring zebra®sh genomic
clones with mice harbouring puffer®sh genomic constructs
would address the issue of whether these splicing differences
truly are teleost speci®c and also serve as a valuable
experimental resource for investigating the mechanism of
such differences.
Faithful expression of a marked Fugu WT1 protein in
transgenic zebra®sh
The sequences regulating the expression of WT1 in vivo have
yet to be identi®ed. The proximal promoter of the human gene
directs variable expression of a reporter gene in transgenic
mice and not in the major site of WT1 expression, the
developing genitourinary system (41). A 280 kb human WT1
yeast arti®cial chromosome (YAC) is required to achieve
correct genitourinary expression of a reporter gene in
transgenic mice (41,42) although expression of this
construct is in¯uenced by its site of integration. Despite the
Figure 4. Expression of full-length protein from a puffer®sh transgene in zebra®sh. (A) Diagram of the genomic Fugu WT1 fragment with C-terminal
b-galactosidase fusion. (B) Expression of endogenous WT1 in control 12 h.p.f. zebra®sh by in situ hybridisation. (C) X-gal-stained transgenic zebra®sh at
~12 h.p.f. Correct splicing of the construct is evident from X-gal staining resulting from production of a fusion protein. The mosaicism associated with
zebra®sh transgenesis results in staining only in one half of the pronephric ®eld. (D and E) Examples of mosaicism observed in pronephric expression of
Fugu WT1±lacZ fusion protein between individual ®sh. Arrowheads point to transgene expression (X-gal staining) in the developing pronephos.
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bene®ts of recombination in yeast to modify constructs, YAC
transgenesis as a means of dissecting gene regulation is costly
and time consuming. The conservation of genitourinary WT1
expression throughout vertebrates suggests that gene regula-
tion studies in lower vertebrates and comparative evolutionary
approaches may be appropriate for WT1. The puffer®sh
genome is approximately 7.5 times smaller than that of human
(17), whilst the Fugu WT1 gene is approximately 15 times
smaller than its human counterpart (10). We demonstrate that,
despite this compaction, the Fugu WT1 gene can faithfully
recapitulate the expression pattern of the endogenous zebra-
®sh WT1 gene when introduced as a transgene.
The inability to detect expression of Fugu WT1 in the
kidneys of transgenic mice may be due to the mammalian
transcription machinery not recognising Fugu WT1 elements
ef®ciently or, as with the analogous human construct, may
re¯ect a great sensitivity to site of integration effects. That a
similar Fugu construct directs reproducible kidney-speci®c
expression in transgenic zebra®sh further strengthens the case
for the Fugu:zebra®sh system as a means of dissecting gene
regulation in vivo, and provides a genetic tool for studying
pronephric development in zebra®sh via transgenesis.
Whilst this study con®rms that Fugu genes do not function
as natural minigenes in transgenic mice, full-length Fugu WT1
with a C-terminal b-galactosidase fusion is correctly spliced
and translated to produce the fusion protein in transgenic
zebra®sh. These studies suggest that Fugu genes will be useful
for functional transgenic experiments in zebra®sh. For
example, Fugu cosmids introduced into zebra®sh mutants
could be employed in transgenic rescue experimentsÐFugu
genes can express faithfully in zebra®sh, Fugu mRNAs can be
processed to give protein and Fugu clones are available `off
the shelf' from the UK HGMP-RC (http://fugu.hgmp.mrc.
ac.uk). Given the increasing number of zebra®sh mutants
available, this approach could have broad implications. The
zebra®sh:Fugu system now represents a powerful and con-
venient tool for dissecting both vertebrate gene regulation and
gene function in vivo and may help in the study of the
fundamental mechanisms underlying vertebrate splicing.
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